Kezar Life Sciences (KZR) Competitors $4.32 +0.02 (+0.47%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. HURA, CLYM, IKT, ZNTL, ENTX, ONCY, OVID, SRZN, IRD, and LFVNShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include TuHURA Biosciences (HURA), Climb Bio (CLYM), Inhibikase Therapeutics (IKT), Zentalis Pharmaceuticals (ZNTL), Entera Bio (ENTX), Oncolytics Biotech (ONCY), Ovid Therapeutics (OVID), Surrozen (SRZN), Opus Genetics (IRD), and Lifevantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors TuHURA Biosciences Climb Bio Inhibikase Therapeutics Zentalis Pharmaceuticals Entera Bio Oncolytics Biotech Ovid Therapeutics Surrozen Opus Genetics Lifevantage Kezar Life Sciences (NASDAQ:KZR) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Is KZR or HURA more profitable? Kezar Life Sciences' return on equity of -63.51% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -63.51% -52.13% TuHURA Biosciences N/A -248.79%-150.83% Do analysts recommend KZR or HURA? Kezar Life Sciences presently has a consensus price target of $9.00, indicating a potential upside of 108.33%. TuHURA Biosciences has a consensus price target of $12.67, indicating a potential upside of 402.65%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, KZR or HURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life SciencesN/AN/A-$83.74M-$9.69-0.45TuHURA BiosciencesN/AN/A-$21.68MN/AN/A Do insiders and institutionals have more ownership in KZR or HURA? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, KZR or HURA? Kezar Life Sciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Does the media refer more to KZR or HURA? In the previous week, Kezar Life Sciences and Kezar Life Sciences both had 1 articles in the media. Kezar Life Sciences' average media sentiment score of 0.95 beat TuHURA Biosciences' score of 0.83 indicating that Kezar Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Kezar Life Sciences Positive TuHURA Biosciences Positive SummaryKezar Life Sciences beats TuHURA Biosciences on 6 of the 11 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.64M$3.42B$6.16B$10.59BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-0.4523.1085.6727.43Price / SalesN/A450.35584.77183.24Price / CashN/A46.1137.3961.86Price / Book0.2710.6812.516.79Net Income-$83.74M-$52.47M$3.32B$276.90M7 Day Performance-1.82%1.08%707.60%0.29%1 Month Performance15.20%16.86%935.16%7.59%1 Year Performance-51.72%16.25%2,403.40%39.41% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.7533 of 5 stars$4.32+0.5%$9.00+108.3%-50.6%$31.64MN/A-0.4560HURATuHURA Biosciences1.5568 of 5 stars$2.43+1.7%$12.67+421.3%N/A$122.14MN/A0.00N/ACLYMClimb Bio4.1416 of 5 stars$2.00+11.1%$9.20+360.0%N/A$121.97MN/A-2.869Trending NewsAnalyst ForecastAnalyst RevisionGap UpIKTInhibikase Therapeutics1.3067 of 5 stars$1.63+1.2%$8.00+390.8%-6.4%$121.46MN/A-0.616ZNTLZentalis Pharmaceuticals1.7313 of 5 stars$1.62-3.6%$5.84+260.5%-45.9%$121.19M$67.43M-0.72160ENTXEntera Bio2.0737 of 5 stars$2.70+1.9%$10.00+270.4%+31.5%$121.01M$180K-10.3820News CoverageHigh Trading VolumeONCYOncolytics Biotech1.9531 of 5 stars$1.17-2.5%$5.00+327.4%-2.4%$120.43MN/A-4.3330Gap UpOVIDOvid Therapeutics4.5376 of 5 stars$1.58-5.4%$3.70+134.2%+43.5%$118.75M$570K-2.9860SRZNSurrozen2.1019 of 5 stars$13.82+0.4%$38.50+178.6%+28.5%$117.98M$10.65M-0.9680IRDOpus Genetics2.1495 of 5 stars$2.00+2.0%$7.33+266.7%N/A$117.42M$10.99M-1.0414News CoveragePositive NewsAnalyst ForecastLFVNLifevantage4.3382 of 5 stars$9.06+1.1%$30.50+236.6%-24.2%$113.71M$228.53M12.24260 Related Companies and Tools Related Companies HURA Competitors CLYM Competitors IKT Competitors ZNTL Competitors ENTX Competitors ONCY Competitors OVID Competitors SRZN Competitors IRD Competitors LFVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
